

Cristina R Ferrone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5408446/cristina-r-ferrone-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184
papers

7,877
citations

42
h-index

86
g-index

201
ext. papers

10,503
ext. citations

5.8
avg, IF

5.67
L-index

#	Paper	IF	Citations
184	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. 2022 , 10,		1
183	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.. <i>Cancer Discovery</i> , 2022 , OF1-OF18	24.4	4
182	Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. <i>Cancer Discovery</i> , 2021 ,	24.4	5
181	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 439-457	7.3	103
180	Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. <i>European Radiology</i> , 2021 , 1	8	0
179	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3773-3777	2.2	3
178	Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 1727-1735	3.3	3
177	Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4216-4224	3.1	3
176	ASO Author Reflections: Long-Term Impact of Pancreatoduodenectomy on Pancreas-Specific Quality of Life. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4225-4226	3.1	
175	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5586-5594	12.9	37
174	Local and systemic recurrence following total neoadjuvant therapy (TNT) and resection for borderline resectable and locally advanced pancreatic adenocarcinoma: Long-term follow up from two phase II studies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4133-4133	2.2	
173	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16253-e16253	2.2	
172	Analysis of in court malpractice litigation following pancreatic surgery. <i>Pancreatology</i> , 2021 , 21, 819-823	3.8	1
171	Clinical impact of PET/MRI in oligometastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021 , 125, 975-982	9.2	3
170	Promoting Women in Academic Medicine during COVID-19 and Beyond. <i>Journal of General Internal Medicine</i> , 2021 , 36, 3292-3294	4	1
169	Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2021 , 274, e134-e142	7.8	17
168	Simulated Volume-Based Regionalization of Complex Procedures: Impact on Spatial Access to Care. <i>Annals of Surgery</i> , 2021 , 274, 312-318	7.8	6

167	Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study. <i>Annals of Surgery</i> , 2021 , 274, e980-e987	7.8	11
166	A Rare Case of Gallbladder Small Cell Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 561-564	3.3	
165	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 182-191	9.7	11
164	Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. <i>American Journal of Surgery</i> , 2021 , 221, 134-140	2.7	2
163	B7-H3: An Attractive Target for Antibody-based Immunotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 1227-1235	10.35	44
162	Size of the Largest Colorectal Liver Metastasis Is an Independent Prognostic Factor in the Neoadjuvant Setting. <i>Journal of Surgical Research</i> , 2021 , 259, 253-260	2.5	2
161	A multi-institutional study of patient-derived gender-based discrimination experienced by resident physicians. <i>American Journal of Surgery</i> , 2021 , 221, 309-314	2.7	0
160	Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. <i>Journal of the American College of Surgeons</i> , 2021 , 232, 361-371	4.4	10
159	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 2859-2870	3.3	0
158	Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 439-439	2.2	
157	Patient and Caregiver Considerations and Priorities When Selecting Hospitals for Complex Cancer Care. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4183-4192	3.1	1
156	Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. <i>Molecular Imaging and Biology</i> , 2021 , 23, 456-466	3.8	8
155	The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 429-429	2.2	1
154	Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4592-4601	3.1	0
153	Fibrohistiocytic Variant of Hepatic Pseudotumor: An Antibiotic Responsive Tumefactive Lesion. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1314-1323	6.7	0
152	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. <i>Annals of Surgery</i> , 2021 , 274, 721-728	7.8	4
151	Which Patient Do I Attend to First? Night-float Simulation to Assess Surgical Interns' Clinical Prioritization Skills. <i>Journal of Surgical Education</i> , 2021 , 78, e226-e231	3.4	
150	CT and MRI features differentiating mucinous cystic neoplasms of the liver from pathologically simple cysts. <i>Clinical Imaging</i> , 2021 , 76, 46-52	2.7	2

149	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021 ,	3.8	3
148	Open hepatic resection in the elderly at two tertiary referral centers. <i>American Journal of Surgery</i> , 2021 , 222, 594-598	2.7	
147	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.. <i>JAMA Oncology</i> , 2021 ,	13.4	1
146	Diagnosis of Depression is Associated with Readmission Following Elective Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4544-4550	3.1	2
145	Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. <i>American Journal of Surgery</i> , 2020 , 220, 1579-1585	2.7	3
144	Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. <i>Clinical Cancer Research</i> , 2020 , 26, 5007-5018	12.9	11
143	A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020 , 18, 255	8.5	3
142	Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. <i>Histopathology</i> , 2020 , 77, 35-45	7.3	4
141	Socioeconomic determinants of the surgical treatment of colorectal liver metastases. <i>American Journal of Surgery</i> , 2020 , 220, 952-957	2.7	2
140	Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. <i>Histopathology</i> , 2020 , 77, 144-155	7.3	3
139	Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. <i>American Journal of Surgery</i> , 2020 , 220, 29-34	2.7	8
138	Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. <i>Pancreatology</i> , 2020 , 20, 691-697	3.8	4
137	Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020 ,	7.8	4
136	Randomized trial of a perioperative geriatric intervention for older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 12012-12012	2.2	19
135	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 159-159	2.2	
134	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e24032-e24032	2.2	
133	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020 ,	7.8	18
132	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 1871-1884	8.8	20

131	Effects of laparoscopic vs open abdominal surgery on costs and hospital readmission rate and its effect modification by surgeons' case volume. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020 , 34, 1-12	5.2	0
130	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020 , 10, e183-e187	2.8	2
129	Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1606-1612 ^{3.1}	3.1	5
128	Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients?. <i>Hpb</i> , 2020 , 22, 1020-1024	3.8	3
127	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1400-1406	3.1	8
126	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1122-1129	3.1	9
125	Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma: A Bi-institutional Analysis. <i>Annals of Surgery</i> , 2020 , 271, 1148-1155	7.8	11
124	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. <i>Annals of Surgery</i> , 2020 , 272, 731-737	7.8	14
123	Reply to G.W. Peters et al and S. Shi et al. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2947-2948	2.2	
122	Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 567289	5.3	3
121	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5161-5172	3.1	3
120	Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2020 , 73, 23-29	3.9	9
119	Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3898-3912	3.1	6
118	Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2019 , 32, 844-854	9.8	2
117	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). <i>Clinical Cancer Research</i> , 2019 , 25, 2644-2655	12.9	34
116	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1020-1027	13.4	205
115	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. <i>Cell</i> , 2019 , 178, 160-175.e27	56.2	211
114	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019 , 9, 1064-1079	24.4	154

113	Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. <i>American Journal of Surgery</i> , 2019 , 218, 959-966	2.7	10
112	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 64-72	4	64
111	Clinical impact of PET/MR in treated colorectal cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2260-2269	8.8	17
110	Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019 , 26, 4091-4099	3.1	14
109	Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. <i>Gastroenterology</i> , 2019 , 157, 720-730.e2	13.3	25
108	Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. <i>Advances in Surgery</i> , 2019 , 53, 253-269	1.2	1
107	Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. <i>Frontiers in Oncology</i> , 2019 , 9, 1085	5.3	26
106	Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 412-412	2.2	1
105	Outcomes following liver SBRT for metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 418-418	2.2	1
104	Pancreatic Adenocarcinoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 202-210	7.3	179
103	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 392-392 ^{2.2}	2.2	1
102	Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. <i>Surgical Oncology Clinics of North America</i> , 2019 , 28, 745-762	2.7	0
101	Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 ,	11.5	34
100	Benchmarks in Pancreatic Surgery: A Novel Tool for Unbiased Outcome Comparisons. <i>Annals of Surgery</i> , 2019 , 270, 211-218	7.8	82
99	Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?. <i>Journal of Gastrointestinal Surgery</i> , 2019 , 23, 1135-1142	3.3	3
98	Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation. <i>Hpb</i> , 2019 , 21, 834-840	3.8	4
97	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019 , 24, 945-954	5.7	9
96	Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. <i>American Journal of Surgery</i> , 2019 , 218, 157-163	2.7	7

95	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. <i>Annals of Surgery</i> , 2019 , 269, 733-740	7.8	151
94	Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019 , 270, 1138-1146	7.8	33
93	Defective HLA class I antigen processing machinery in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 999-1009	7.4	42
92	Staging Laparoscopy Not Only Saves Patients an Incision, But May Also Help Them Live Longer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 1009-1016	3.1	23
91	Hospital readmission after distal pancreatectomy is predicted by specific intra- and post-operative factors. <i>American Journal of Surgery</i> , 2018 , 216, 511-517	2.7	4
90	Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. <i>Nuclear Medicine and Biology</i> , 2018 , 58, 67-73	2.1	26
89	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 963-969	13.4	253
88	Neoadjuvant Chemotherapy in Pancreatic Cancer 2018 , 1187-1202		1
87	Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery. <i>Journal of Magnetic Resonance Imaging</i> , 2018 , 47, 425-432	5.6	20
86	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. <i>Annals of Surgery</i> , 2018 , 267, 157-163	7.8	66
85	Effects of Intraoperative Fluid Management on Postoperative Outcomes: A Hospital Registry Study. <i>Annals of Surgery</i> , 2018 , 267, 1084-1092	7.8	110
84	Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 656-661	2.7	9
83	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2018 , 268, 340-347	7.8	26
82	Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. <i>JAMA Surgery</i> , 2018 , 153, 809-815	5.4	62
81	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018 , 18, 166-181	2.2	7
80	Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. <i>DMM Disease Models and Mechanisms</i> , 2018 , 11,	4.1	25
79	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4116-4116	2.2	8
78	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 272-272	2.2	3

77	Hepatocellular carcinoma surgical therapy: perspectives on the current limits to resection. <i>Chinese Clinical Oncology</i> , 2018 , 7, 48	2.3	15
76	ASO Author Reflections: Staging Laparoscopy Improves Overall Survival of Patients with Pancreatic Adenocarcinoma Found to Have Occult Metastatic Disease. <i>Annals of Surgical Oncology</i> , 2018 , 25, 830-831 ¹		
75	Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3936-3942	3.1	8
74	Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 4020-4026	3.1	30
73	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 4027-4034	3.1	10
72	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. <i>Practical Radiation Oncology</i> , 2018 , 8, 414-421	2.8	11
71	Acinar cell cystadenoma: A challenging cytology diagnosis, facilitated by moray micro-forceps biopsy. <i>Diagnostic Cytopathology</i> , 2017 , 45, 557-560	1.4	17
70	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	53
69	Potential impact of a volume pledge on spatial access: A population-level analysis of patients undergoing pancreatectomy. <i>Surgery</i> , 2017 , 162, 203-210	3.6	25
68	Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2017 , 116, 658-664	2.8	21
67	Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3203-3211	3.1	24
66	After Neoadjuvant Therapy, Imaging No Longer Provides a Clear Answer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 300	4	2
65	Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. <i>Pancreatology</i> , 2017 , 17, 920-926	3.8	21
64	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017 , 357, 1156-1160	33.3	577
63	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. <i>Cancer Letters</i> , 2017 , 409, 9-19	9.9	33
62	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. <i>Gastroenterology</i> , 2017 , 153, 1284-1294.e1	13.3	119
61	Primary lymph node gastrinoma: A single institution experience. <i>Surgery</i> , 2017 , 162, 1088-1094	3.6	8
60	Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. <i>Liver Cancer</i> , 2017 , 6, 360-374	9.1	44

59	Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2017 , 21, 1831-1840	3.3	10
58	Diverse repetitive element RNA expression defines epigenetic and immunologic features of colon cancer. <i>JCI Insight</i> , 2017 , 2, e91078	9.9	13
57	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4113-4113	2.2	1
56	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4118-4118	2.2	4
55	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 368-368	2.2	1
54	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 386-386	2.2	11
53	Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017 , 8, 37646-37656	3.3	17
52	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4117-4117	2.2	
51	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 470-8	12.9	124
50	Late Pancreatic Fistula After Pancreaticoduodenectomy: A Case Report and Review of the Literature. <i>Case Reports in Pancreatic Cancer</i> , 2016 , 2, 65-70		2
49	Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. <i>Cancer Discovery</i> , 2016 , 6, 852-69	24.4	213
48	The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. <i>Annals of Surgical Oncology</i> , 2016 , 23, 290-6	3.1	58
47	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 460-8	2.2	257
46	Spectrum and Classification of Cystic Neoplasms of the Pancreas. <i>Surgical Oncology Clinics of North America</i> , 2016 , 25, 339-50	2.7	11
45	Discordance Between Perioperative Antibiotic Prophylaxis and Wound Infection Cultures in Patients Undergoing Pancreaticoduodenectomy. <i>JAMA Surgery</i> , 2016 , 151, 432-9	5.4	60
44	Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2016 , 20, 277-83	3.3	28
43	Primary Hepatic Gastrinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016 , 20, 662-3	3.3	4
42	Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 393-393	2.2	1

41	Surgical management of intrahepatic cholangiocarcinoma in the modern era: advances and challenges. <i>Chinese Clinical Oncology</i> , 2016 , 5, 9	2.3	10
40	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 376-376	2.2	
39	Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the Massachusetts General Hospital. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016 , 23, 181-7	2.8	44
38	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2016 , 23, 609-617	3.1	16
37	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2016 , 6, 727-39	24.4	94
36	"Idealized" vs. "True" learning curves: the case of laparoscopic liver resection. <i>Hpb</i> , 2016 , 18, 504-9	3.8	21
35	A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. <i>Biomaterials</i> , 2016 , 93, 71-82	15.6	27
34	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016 , 20, 953-9	3.3	10
33	Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. <i>Advances in Surgery</i> , 2016 , 50, 115-28.2		4
32	Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. <i>Nature</i> , 2015 , 524, 361-5	50.4	475
31	Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. <i>Surgery</i> , 2015 , 158, 1219-25	3.6	32
30	Endovascular diagnosis of radiographically and intraoperatively occult insulinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015 , 26, 760-2	2.4	
29	Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. <i>Journal of the American College of Surgeons</i> , 2015 , 220, 839-44	4.4	46
28	The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. <i>Surgery</i> , 2015 , 157, 881-7	3.6	61
27	Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. <i>Annals of Surgery</i> , 2015 , 261, 12-7	7.8	544
26	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015 , 20, 1019-27	5.7	88
25	Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care?. <i>Journal of the American College of Surgeons</i> , 2015 , 221, 1015-22	4.4	38
24	Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. <i>Molecular Oncology</i> , 2015 , 9, 1982-93	7.9	14

23	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4020-4020	2.2	1
22	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. <i>Practical Radiation Oncology</i> , 2014 , 4, e117-e123	2.8	4
21	Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. <i>Journal of Gastrointestinal Surgery</i> , 2014 , 18, 137-44; discussion 144-5	3.3	67
20	Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. <i>Seminars in Oncology</i> , 2014 , 41, 685-99	5.5	8
19	Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. <i>Surgery</i> , 2014 , 156, 611-21	3.6	53
18	In response to Birgir Gudjonsson, MD. <i>Surgery</i> , 2014 , 156, 1286	3.6	1
17	Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. <i>Cell Reports</i> , 2014 , 8, 1905-1918	10.6	339
16	Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. <i>Nature</i> , 2014 , 513, 110-4	50.4	288
15	A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 830-8	4	81
14	Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014 , 110, 160-4	5.3	21
13	HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. <i>Neoplasia</i> , 2014 , 16, 31-42	6.4	72
12	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4128-4128	2.2	1
11	Variability in immune infiltrates and HLA expression in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 230-230	2.2	2
10	Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. <i>World Journal of Gastrointestinal Surgery</i> , 2014 , 6, 136-41	2.4	5
9	Genomic profiling of intrahepatic cholangiocarcinoma: Refining prognostic determinants and identifying therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 210-210	2.2	1
8	Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. <i>Cancer</i> , 2013 , 119, 4196-204	6.4	48
7	FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. <i>Oncologist</i> , 2013 , 18, 543-8	5.7	213
6	Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?. <i>Annals of Surgery</i> , 2013 , 257, 731-6	7.8	295

5	Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. <i>Surgery</i> , 2012 , 152, S43-9	3.6	154
4	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4021-4021	2.2	
3	Twenty-three years of the Warshaw operation for distal pancreatectomy with preservation of the spleen. <i>Annals of Surgery</i> , 2011 , 253, 1136-9	7.8	98
2	Current trends in pancreatic cystic neoplasms. <i>Archives of Surgery</i> , 2009 , 144, 448-54		126
1	Pancreatic fistula rates after 462 distal pancreatectomies: staplers do not decrease fistula rates. <i>Journal of Gastrointestinal Surgery</i> , 2008 , 12, 1691-7; discussion 1697-8	3.3	194